Forsta AP Fonden Sells 2,660 Shares of Amgen Inc. $AMGN

Forsta AP Fonden trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 113,340 shares of the medical research company’s stock after selling 2,660 shares during the quarter. Forsta AP Fonden’s holdings in Amgen were worth $37,097,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of AMGN. Robeco Institutional Asset Management B.V. boosted its stake in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $1,669,000. Jones Financial Companies Lllp boosted its stake in shares of Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after purchasing an additional 6,115 shares in the last quarter. Adell Harriman & Carpenter Inc. boosted its stake in shares of Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $22,441,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 0.1%

NASDAQ:AMGN opened at $336.79 on Friday. The firm’s 50 day simple moving average is $342.53 and its 200 day simple moving average is $345.33. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The company has a market cap of $181.77 billion, a PE ratio of 23.44, a P/E/G ratio of 3.38 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.0%. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AMGN shares. Truist Financial raised their price target on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. The Goldman Sachs Group raised their price target on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Leerink Partners restated a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target on the stock. Finally, Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $355.19.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.